Information Provided By:
Fly News Breaks for November 10, 2015
IMGN
Nov 10, 2015 | 08:30 EDT
After ImmunoGen presented updated mirvetuximab soravtansine Phase 1 data, Oppenheimer says that the drug showed "clear anti-tumor activity." The firm thinks that ImmunoGen's data compares favorably with that of AstraZeneca (AZN). Oppenheimer keeps a $24 price target and Outperform rating on ImmunoGen.
News For IMGN From the Last 2 Days
There are no results for your query IMGN